🔎 Trials Near Me

Beranda › Kanker Paru Non-Sel Kecil › New Hampshire

Uji klinis Kanker Paru Non-Sel Kecil di New Hampshire

17 studi untuk Kanker Paru Non-Sel Kecil mencari peserta di lokasi di New Hampshire.

Kota di New Hampshire

Teks studi resmi (Bahasa Inggris)

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

  • Dartmouth-Hitchcock Medical Center /ID# 277673, Lebanon
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT07155187

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • New Hampshire Oncology Hematology PA-Concord, Concord
  • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
  • Solinsky Center for Cancer Care, Manchester
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT04267848

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  • Dartmouth-Hitchcock Medical Center, Lebanon
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT06881784

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  • Dartmouth Hitchcock Medical Center, Lebanon
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06667076

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  • Dartmouth-Hitchcock Medical Center, Lebanon
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06890598

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

  • Clinical Study Site, Lebanon
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT06767514

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

  • Dartmouth Hitchcock Medical Center, Lebanon
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT04302025

A Phase 1/1b Study of IAM1363 in HER2 Cancers

  • Dartmouth Hitchcock Medical, Lebanon
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06253871

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  • Dartmouth-Hitchcock Medical Center, Lebanon
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT06119581

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

  • Dartmouth Hitchcock Medical Center ( Site 0016), Lebanon
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT04165798

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

  • Dartmouth Hitchcock Medical Center ( Site 0016), Lebanon
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT04165070

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

  • New Hampshire Oncology Hematology PA-Concord, Concord
  • Solinsky Center for Cancer Care, Manchester
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Jun 2026 · NCT05642572

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

  • New Hampshire Oncology Hematology PA-Concord, Concord
  • Solinsky Center for Cancer Care, Manchester
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Mei 2026 · NCT06116682

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

  • New Hampshire Oncology Hematology PA-Concord, Concord
  • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
  • Solinsky Center for Cancer Care, Manchester
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Mei 2026 · NCT06616584

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

  • New Hampshire Oncology Hematology PA-Concord, Concord
  • Solinsky Center for Cancer Care, Manchester
Menerima pesertaFase 2
18 Minutes · Semua jenis kelamin · Diperbarui 5 Mei 2026 · NCT06031688

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

  • Dartmouth Hitchcock, Lebanon
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Apr 2026 · NCT06362369

A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors

  • Dartmouth Hitchcock Medical Center, Lebanon
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Mar 2026 · NCT05948865

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.